Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Miransertib (Primary)
- Indications Proteus syndrome
- Focus Pharmacodynamics; Pharmacokinetics
- 09 Nov 2017 Preliminary data presented at the Proteus Syndrome Foundation Family Conference in September 2017, according to an ArQule, Inc. media release.
- 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 20 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.